News

CritiTech Announces New CEO

June 4, 2009

FOR IMMEDIATE RELEASE

LAWRENCE, Kan. CritiTech's Chairman and President, Sam Campbell announced today that Dr. David Johnston has been named CritiTech's CEO. Dr. Johnston is a highly qualified executive with extensive leadership experience in non-clinical chemistry (chemistry, pharmaceutical product development) and clinical development (Phase I through Phase IV), regulatory approval, technology transfer, international operations, sales and marketing, and brand management. Campbell says, "With Dr. Johnston's extensive experience, he will help elevate and expand CritiTech's ability to develop and commercialize pharmaceutical products." Dr. Johnston most recently served as the interim President and CEO for AerovectRX, Inc., a spin out from the Center for Disease Control. Previously, he served as Sr. Vice President of R&D for Nektar Therapeutics with responsibility for Nektar's research and development activities world-wide. In addition to his R&D responsibilities, he was Director of Nektar ( UK ), Chairman of Nektar India (Pvt.) Ltd., and a member of the Joint Development Committees for all of their leading pharmaceutical partnerships. Prior to this role, he was chief development officer for Control Delivery Systems. He formerly was President and COO of AAI International directing all of the CRO business in North America, Europe, and Mainland China. Dr. Johnston has held international leadership positions with Oread, Inc., Sanofi-Winthrop and Sterling Winthrop and is currently on the board of Wilmington Pharmaceuticals and the advisory board of Velquest Inc.

Dr. Johnston received his Ph.D. in Organic Chemistry from St. Andrews University , St. Andrews Scotland and did his Post Doctoral Studies at Max Planck Institute, Heidelberg, Germany.

CritiTech, Inc. currently has their oncology drug Nanotax® in a Phase I Clinical Trial at the Kansas University Cancer Center and is progressing with additional drug candidates in preclinical stages. CritiTech, Inc. opened its laboratory in June, 2004 at the West Lawrence Labs located at 4950 Research Park Way in Lawrence, Kansas. CritiTech provides critical drug delivery and development technology for the pharmaceutical industry through its patented nanoparticle production technology originally developed at the University of Kansas.